nitroxoline has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dattola, F; Gobec, S; Kos, J; Marcello, A; Martínez-Orellana, P; Milan Bonotto, R; Mitrović, A; Sosič, I | 1 |
1 other study(ies) available for nitroxoline and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
Topics: Antiviral Agents; Cathepsin B; COVID-19; Humans; SARS-CoV-2; Virus Internalization | 2023 |